Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $21

Morgan Stanley analyst Matthew Harrison maintains Prime Medicine (NASDAQ:PRME) with a Equal-Weight and lowers the price target from $23 to $21.
byBenzinga Newsdesk
January 24, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Matthew Harrison maintains Prime Medicine (NASDAQ:PRME) with a Equal-Weight and lowers the price target from $23 to $21.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts